Legato Capital Management LLC acquired a new position in Haemonetics Corporation (NYSE:HAE – Free Report) during the fourth quarter, Holdings Channel reports. The institutional investor acquired 13,194 shares of the medical instruments supplier’s stock, valued at approximately $1,057,000.
Other hedge funds have also recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Haemonetics by 3.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,541 shares of the medical instruments supplier’s stock valued at $1,877,000 after purchasing an additional 971 shares during the last quarter. Caxton Associates LLP acquired a new position in Haemonetics during the first quarter valued at approximately $216,000. United Services Automobile Association acquired a new position in Haemonetics during the first quarter valued at approximately $212,000. Empowered Funds LLC grew its holdings in Haemonetics by 9.1% during the first quarter. Empowered Funds LLC now owns 4,458 shares of the medical instruments supplier’s stock valued at $283,000 after purchasing an additional 372 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in Haemonetics by 6.2% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 156,138 shares of the medical instruments supplier’s stock valued at $9,923,000 after purchasing an additional 9,051 shares during the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.
Wall Street Analysts Forecast Growth
Several brokerages have commented on HAE. Robert W. Baird set a $67.00 price target on Haemonetics in a report on Friday, May 8th. JPMorgan Chase & Co. lowered their price target on Haemonetics from $74.00 to $62.00 and set a “neutral” rating on the stock in a report on Friday, May 8th. Weiss Ratings downgraded Haemonetics from a “hold (c-)” rating to a “sell (d+)” rating in a report on Thursday. BTIG Research reiterated a “buy” rating and set a $88.00 price target on shares of Haemonetics in a report on Friday, February 6th. Finally, Barrington Research lowered their price target on Haemonetics from $94.00 to $89.00 and set an “outperform” rating on the stock in a report on Tuesday, May 12th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Haemonetics presently has an average rating of “Moderate Buy” and an average target price of $77.11.
Haemonetics Stock Down 0.0%
HAE opened at $65.48 on Monday. Haemonetics Corporation has a 1-year low of $47.31 and a 1-year high of $87.32. The company has a current ratio of 2.95, a quick ratio of 1.87 and a debt-to-equity ratio of 1.53. The stock has a market capitalization of $2.98 billion, a price-to-earnings ratio of 32.42, a P/E/G ratio of 1.32 and a beta of 0.53. The business has a 50 day moving average of $58.23 and a 200-day moving average of $67.21.
Haemonetics (NYSE:HAE – Get Free Report) last posted its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $1.29 earnings per share for the quarter, beating the consensus estimate of $1.28 by $0.01. Haemonetics had a return on equity of 27.30% and a net margin of 7.29%.The company had revenue of $346.35 million during the quarter, compared to analysts’ expectations of $336.83 million. During the same period in the prior year, the business earned $1.24 earnings per share. Haemonetics’s revenue for the quarter was up 4.8% compared to the same quarter last year. Haemonetics has set its FY 2027 guidance at 5.258-5.307 EPS. As a group, sell-side analysts anticipate that Haemonetics Corporation will post 5.23 earnings per share for the current year.
About Haemonetics
Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.
The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.
Featured Stories
- Five stocks we like better than Haemonetics
- The Smart Glasses Gold Rush Is Leaving Old-School Eyewear Behind
- 3 Rare Earth Stocks That Win No Matter What China Does Next
- Amylyx Stock: Why the Full Pipeline Story Matters
- Palantir and Dell Build an AI OS for the Paranoid
Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Corporation (NYSE:HAE – Free Report).
Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.
